MedTrace Logo

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions

NCT00870974 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2017-01-06

No results posted yet for this study

Summary

Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease (PD), Huntington disease (HD), Fragile X syndrome (FXS), Autism Spectrum Disorder(ASD), Alzheimer's Disease(AD), and subjects with mild cognitive impairment (MCI).

The goal of this study is to assess \[18F\]F-PEB positron emission tomography (PET) imaging as a tool to detect mGluR5 density in the brain of PD, HD, FXS ASD, AD, and MCI research participants and similarly aged healthy subjects.

Conditions

  • Parkinson Disease
  • Huntington Disease
  • Autistic Spectrum Disorders
  • Fragile X Syndrome
  • Alzheimer Disease
  • Mild Cognitive Impairment

Interventions

DRUG

[18F]FPEB

Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]F-PEB

Sponsors & Collaborators

  • Institute for Neurodegenerative Disorders

    lead OTHER

Principal Investigators

  • David Russell, MD · Institute for Neurodegenerative Disorders

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2016-10-31
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00870974 on ClinicalTrials.gov